India, Jan. 23 -- This mid-cap Pharma stock, engaged in developing and manufacturing APIs, formulations, and biotech products for global pharma clients in anti-retroviral, oncology, and generics, jumped 5.50 percent after the company reported December quarterly results with a 179 percent YoY increase in net profit.

With a market capitalization of Rs. 54,525.51 crores, the share of Laurus Labs Limited has reached an intraday high of Rs. 1,059.95 per equity share, rising nearly 5.5 percent from its previous day's close price of Rs. 1,004.95. Since then, the stock has retreated and is currently trading at Rs. 1,010 per equity share.

Q3 FY26 Result Walkthrough Coming into the quarterly results of Laurus Labs Limited, the company's consolida...